All posts by imreal

Zego’s Dirk Wakeham to Speak at Multifamily Operations Summit


News Image

“While the industry has adapted quickly during these last few months, it is now time for property owners to examine the future transformations that will be required and will allow them to remain competitive.”

Today, Zego (Powered by PayLease), the property technology company that powers better resident engagement & efficiency for multifamily and HOA communities, is announcing that CEO Dirk Wakeham will be a featured speaker at the Multifamily Operations Summit, a virtual event for Executives, Investors/Owners, Technology professionals, Onsite Property Managers, Leasing Professionals, and more.

“The pandemic shined a light on critical changes required to propel the residential real estate industry into its next phase,” said Wakeham. “While the industry has adapted quickly during these last few months, it is now time for property owners to examine the future transformations that will be required and will allow them to remain competitive. I’m honored to join the Multifamily Operations Summit as this esteemed group of experts helps the industry adjust and address what’s necessary in our post-COVID world.”

WHO: Multifamily professionals who are looking to get the tools, strategies, capabilities, and mindset for what is working today in Multifamily

WHAT: Two-day live virtual summit featuring seasoned experts from the multifamily industry on best practices for growing your business and adapting to the changing climate

WHEN: Friday, June 25, 2020 at 10:00am PT

WHERE: Join the free live broadcast from the Studio in Scottsdale, AZ

Zego provides a comprehensive resident engagement platform that unifies critical resident touch-points—from online payments and utilities, to communication and smart devices—into one app, and serves 6,000 residential real estate companies and over 12 million units nationwide.

About Zego

Zego (Powered by PayLease) is a property technology company that frees management companies and community associations to go above and beyond for their residents. Zego’s mobile-first engagement platform for the residential real estate industry unifies the most critical resident touch-points into one app. From payments and utilities, to communications and smart devices, everything is seamlessly integrated into your back-end system. Zego delivers portfolio-wide efficiency, higher NOI, and more engaged residents. Learn more about how Zego drives community engagement and efficiency at gozego.com.

Share article on social media or email:

LaVoieHealthScience Forms Strategic Alliance with Bioscience Valuation BSV GmbH


“We look forward to working with Joachim and the BSV team to help our clients succeed, by helping them effectively communicate their true value proposition to investors, licensing partners and other key stakeholders,” said Donna L. LaVoie, President, CEO, and Founder of LaVoieHealthScience.

LaVoieHealthScience (“LHS”) and Bioscience Valuation BSV GmbH (“BSV”) today announced a strategic alliance between the two firms. The alliance combines LHS’ expertise in strategic communications for companies at the forefront of health and science innovation with BSV’s skill in providing strategic valuation assessments for life science companies. The strategic alliance is the second signed in 2020 for both firms. On January 9, 2020, LHS inked a global strategic alliance with Omnicom Public Relations Group (OPRG), a division of Omnicom Group, bringing clients a broader set of integrated health-and science-experienced teams.

Bioscience Valuation provides evidence-based value, commercial, R&D, and economic assessments to pharmaceutical and biotechnology companies to support investment and partnering decisions. With more than 500 life-science and healthcare consulting engagements undertaken by BSV since its founding in 2000, the firm’s evidence-driven analyses help company management validate and communicate the value of their businesses to stakeholders and investors.

“Our strategic alliance with BSV will ensure that LHS clients have a roadmap for understanding the value of their strategic assets,” said Donna L. LaVoie, President, CEO, and Founder of LaVoieHealthScience, “We look forward to working with Joachim and the BSV team to help our clients succeed, by helping them effectively communicate their true value proposition to investors, licensing partners and other key stakeholders.”

Dr. Joachim Greuel, MBA, Managing Director and Co-Founder of Bioscience Valuation BSV GmbH said, “We are excited to work closely with LHS and their clients. Companies must be able to communicate the value of their products based on market evidence to succeed in the life science sector. This strategic alliance will help LHS’ clients maximize value in licensing deals and funding rounds, optimize investment decisions, and better assess the competitive landscape. And it will give our clients access to LHS’ strategic communications and IR programming capabilities to communicate their company’s value proposition to the marketplace.”

About LaVoieHealthScience

LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications, relationship building and marketing. The firm provides strategic consulting, public relations and investor relations to build recognition and increase sales and value for health science innovations and has two trademarked methodologies for its strategic communications’ advisory services. The agency has received over 50 awards in recognition of the work done by its strategic thinkers for health and science industry-leading clients. LHS was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies, as well as ranked on the O’Dwyer’s list of 2020 Healthcare Public Relations Firms and Boston Business Journal’s Largest PR Firms in Massachusetts.

About Bioscience Valuation BSV GmbH

Founded in 2000, Bioscience Valuation BSV GmbH is a leading life science valuation company operating on a global scale. The company uses its sharp quantitative analysis skills to help clients in the healthcare sector asses the economic value of their products and communicate the findings in an optimal way. The services provided by Bioscience Valuation form the foundation for a well-informed, highly rational and value-maximizing strategic decision-making process and a persuasive evidence-based valuation of their biotech or pharmaceutical products.

Contacts

Agency and Media:

Katie Gallagher

Account Director, PR and Marketing

617-792-3937

kgallagher@lavoiehealthscience.com

Share article on social media or email:

Mid-Atlantic BioTherapeutics Inks Deal with Wunderkind™ to Deploy Viral Outbreak Warning System (VOWS™)


Wunderkind has both deep experience in health technology, as well as expertise in leveraging AI to perform real-time identity resolution and infer patterns from deep and disparate datasets such as anonymous social media actions.

Mid-Atlantic BioTherapeutics (MABT) has engaged with New York-based technology firm Wunderkind, LLC to develop and deploy the Viral Outbreak Warning System (VOWS™) platform. VOWS™ is an artificial intelligence/machine learning (AI/ML)-driven technology system that will analyze a broad set of both public and private data in order to accurately identify viral infection hot zones and predict future outbreaks.

As all are now aware, viral pandemics represent a catastrophic medical, societal, and economic burden to humanity. Health security stakeholders such as healthcare systems, local and federal health agencies, insurance companies and NGOs have an urgent need for predictive algorithms that can better monitor potential viral outbreaks in order to mobilize effective prevention and treatment countermeasures.

There is an urgent global need right now for enhanced predictive surveillance. Resurgence of SARS-CoV-2/COVID-19 transmission is already evident as societies reopen, thus highlighting the value of implementing the VOWS™ platform as soon as possible to identify hot zones as they occur.

In order to meet this need, MABT and Wunderkind™ expect that the first working prototype of the VOWS™ platform will be available by late 2020.

VOWS™ will continuously ingest huge amounts of data from a diverse set of sources such as CDC, ClinicalTrials.gov, hospitals, insurance companies, pharmacies, PubMed, and social networks such as Facebook, Twitter, Instagram, etc. Where required, the data will be anonymized and protected utilizing trustless decentralized blockchain strategies.

Then, VOWS’s proprietary AI analysis and interactive visualization tools will identify and correlate critical ‘cause and effect’ relationships between previously unconnected variables leading to disease and outbreak trends.

Although the current focus is addressing the essential needs of the moment, the VOWS™ platform has applications beyond the current pandemic. It will also be useful for surveilling influenza and other infectious diseases (e.g., Ebola, Marburg), future novel virus outbreaks, and even opioid-related events.

There is considerable excitement about VOWS’s potential as a disease surveillance game-changer. Mid-Atlantic BioTherapeutics has received interest from a range of government and industry organizations looking to support the development and deployment of the VOWS™ technology.

Tammo Mueller, Co-Founder & CEO of Wunderkind, LLC commented, “We are very excited to work with Mid-Atlantic BioTherapeutics on VOWS™. As everyone is aware now, the potential benefits to identifying viral infection hot zones, and predicting future outbreaks cannot be overstated. We believe that our expertise in AI and Blockchain will allow us to rapidly deliver a first iteration of the platform.”

David Jobes, Ph.D., Co-Founder & President of Mid-Atlantic BioTherapeutics noted that “It didn’t take long for us to realize that Wunderkind was the right choice to be our VOWS™ technology partner. Not only do they have deep experience in various aspects of health technology, their expertise also includes leveraging AI to perform real-time identity resolution and infer patterns from deep and disparate datasets such as anonymous social media actions. They have the toolbox we needed.”

About Mid-Atlantic BioTherapeutics

Mid-Atlantic BioTherapeutics (http://mabt.us) was founded in 2011 with the mission of eradicating infectious diseases. MABT is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of novel anti-infective approaches such as the patented IMT504 technology platform that harnesses the body’s own immune response to fight off infections. The company is actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases, emerging infectious diseases and biodefense.

About Wunderkind™

Wunderkind™ (http://wunderkind.nyc) is a boutique technology consultancy and product studio that provides guidance and collaboration from the formulation of business and product strategies all the way to final implementation for a diverse set of clients in healthcare, data-driven marketing, commerce, finance, and digital transformation & AI. Wunderkind™ creates near- and long-term strategies for clients to stay ahead of marketplace disruption through the design and deployment of innovative solutions that utilize emerging technologies such as AI and blockchain.

Share article on social media or email:

Ortho Sport & Spine Physicians Invests in New Technology That Allows Patients Same Day Outpatient Diagnosis and Treatment


News Image

With the new NanoScope system, our specialists can now arthroscopically enter, visualize, and treat joints and areas we were previously unable to be safely worked, says Dr. Phillip Langer – Medical Director of Orthopedic Sports Medicine at Ortho Sport & Spine Physicians

Ortho Sport & Spine Physicians is a leading orthopedic and sports medicine practice, serving patients throughout the greater Atlanta metropolitan area and the southeastern United States. Their expert medical team specializes in providing cutting-edge, minimally invasive treatments for complex neck and spine problems, as well as sports-related injuries and conditions. In that spirit, Dr. Langer has begun utilizing the revolutionary NanoScope™ visualization system, which is a needle-sized, 1.9 mm chip-on-tip scope. It aids surgeons in diagnosing conditions such as arthritis and cartilage injuries and can even facilitate orthopedic procedures in joints, such as the shoulder, knee, elbow, wrist and ankle. Ortho Sport & Spine Physicians has long been a leader in using innovative techniques to deliver the most advanced care to patients to improve their experience and outcomes. This advanced system is a real differentiator for the practice, as the NanoScope is still a relatively new technology.

The NanoScope visualization system, developed and manufactured by Arthrex Inc. (Naples, FL), combines leading-edge technology in imaging sensors, LED light and image management that allows surgeons to perform minimally invasive arthroscopy and guide injections in tighter joint spaces that have previously been difficult to visualize. The NanoScope system allows for high-resolution visualization.

“With the new NanoScope system, our specialists can now arthroscopically enter, visualize, and treat joints and areas we were previously unable to be safely worked. This is the future of sports medicine,” says Dr. Phillip Langer – Medical Director of Orthopedic Sports Medicine at Ortho Sport & Spine Physicians

More about Ortho Sport & Spine Physicians:

Ortho Sport & Spine Physicians has multiple locations in the Atlanta area, throughout Georgia and in Charleston, SC. This practice is nationally recognized in orthopedic sports medicine and interventional spine treatment, providing exceptional and personalized care to all patients. They utilize cutting-edge, minimally invasive treatments for complex neck, spine problems and sports injuries. Their lower patient-to-provider ratio, experienced physicians, state-of-the-art facilities and equipment set them apart from other spine, sports medicine and orthopedic practices.

For more information about the services provided by Ortho Sport & Spine Physicians, please call their office at 678-752-7246, or visit their website at http://www.orthosportandspine.com.

Share article on social media or email:

Allora USA Releases a Guide on How to Make Your House Handicap Accessible


News Image

The graphic features more than a dozen tips to make your home more handicap accessible, including recommendations for the kitchen, bathroom, doorways, hallways, and flooring.

Allora USA has announced the release of their newest infographic: How to Make Your House Handicap Accessible.

“You should choose a firm and slip-resistant flooring and ensure that the carpet is not too thick,” according to the graphic.

The graphic features more than a dozen tips to make your home more handicap accessible, including recommendations for the kitchen, bathroom, doorways, hallways, and flooring.

Very few of these tips require professional maintenance, and many can be done DIY with just a little research and preparation. For example, installing maneuverable faucets in the kitchen and accessible outlets throughout the house.

However, for projects that require more overhaul in the house, like widening hallways or changing floors, consider consulting a professional.

To learn more about making your home handicap accessible, visit Allora USA here.

About Allora USA:

The cost of renovating your kitchen or bathroom to be American with Disabilities Act Compliant can be both a costly and overwhelming project to undertake. That’s why we at Allora USA understand that you are expecting results that last a lifetime. With that in mind, we provide products that cater to your needs.

Share article on social media or email:

MEDPLI Now Offering Malpractice Insurance for Private Practice OB/GYNs


“OB/GYN medical malpractice insurance is so expensive that it can prevent doctors from opening their own practice. My goal is to bring new opportunities to these physicians by offering them affordable malpractice insurance without compromising on coverage.”

MEDPLI, the independent medical malpractice insurance provider, is now offering malpractice insurance to solo doctors and small groups of physicians that practice Obstetrics and Gynecology.

OB/GYNs are in demand across the country, but the risk of medical malpractice lawsuits hinders doctors from going into private practice. Reasons for this include the high expense of malpractice insurance for OB/GYNs and difficulty in navigating the insurance marketplace. To help solo doctors and small groups find comprehensive and affordable insurance, MEDPLI is expanding its insurance brokerage services to Private Practice OB/GYNs Reasons for this include the high expense of malpractice insurance for OB/GYNs and difficulty in navigating the insurance system. To help solo doctors and small groups find comprehensive and affordable insurance, MEDPLI is expanding its insurance brokerage services to Private Practice OB/GYNs.

“MEDPLI’s focus is to help solo physicians and small groups, because these are the doctors that need the most guidance through the minefield of malpractice insurance,” says Max Schloemann, CEO of MEDPLI. “OB/GYN medical malpractice insurance is so expensive that it can prevent a doctor, or a small group of doctors, from opening their own practice. My goal is to bring new opportunities to these physicians by offering them affordable malpractice insurance without compromising on coverage. We currently help OB/GYNs in more than 30 states.”

A key aspect to helping solo OB/GYNs and small groups is making sure they obtain coverage from A-rated carriers. “We only recommend carriers that have an A-rating from A.M. Best,” explains Max Schloemann. “A.M. Best vets insurance companies and gives an A-rating to those that are able to protect their policyholders, even during times of increased claim payouts and financial downturns.”

OB/GYNs’ long tail exposure make them more susceptible to a lawsuit. Even the most highly skilled and caring Obstetricians face uncertainty that can lead to claims, and legal defense costs can escalate into six figures. By offering insurance from A-rated carriers, MEDPLI is helping OB/GYNs be protected for the long-term in the event of failed tubal litigation, bowel perforation, shoulder dystocia, poorly performed cesarean sections, and maternal or fetal death. MEDPLI recommends getting a policy with defense costs in addition to the policy’s stated limits of liability. For more tips on buying malpractice insurance, doctors can visit https://medpli.com/buying-malpractice-insurance-101-a-guide-for-physicians/.

MEDPLI is presently working with Private Practice OB/GYNs in most states. If you are an OB/GYN in search of medical malpractice insurance, contact MEDPLI for a quote tailored to your needs. Learn more at https://medpli.com/specialties/obgyn-medical-malpractice-insurance/

Share article on social media or email:

NFP Acquires Leavitt Insurance Services of San Diego, Expanding Property and Casualty and Employee Benefits Capabilities


News Image

“It’s exciting to welcome the LIASD team to NFP and expand our presence and capabilities in an important area of our region,” said John Hohman.

NFP, a leading insurance broker and consultant that provides property and casualty (P&C), corporate benefits, retirement, and individual solutions, today announced the acquisition of Leavitt Insurance Agency of San Diego, Inc. (LIASD) in a transaction that closed effective May 1, 2020.

LIASD is a P&C and employee benefits broker located in San Diego, CA, that focuses on commercial clients and mid-sized employers in southern California. The acquisition scales NFP’s presence in San Diego, adds middle-market commercial P&C capabilities and employee benefits brokerage expertise, and creates a consolidated, full-service office. Art Morgenstein, a senior vice president who joined NFP in February 2020, leads NFP’s San Diego office. Art’s insurance industry experience spans more than four decades and includes account executive, underwriting and senior leadership roles with several international brokerage firms.

“It’s exciting to welcome the LIASD team to NFP and expand our presence and capabilities in an important area of our region,” said John Hohman. “NFP remains focused on growing in key markets and elevating our ability to help clients emerge stronger from this crisis. The addition of LIASD and Art’s continued leadership enhance our ability to achieve these objectives.”

“I’m looking forward to working with the LIASD team and creating new relationships and opportunities,” said Art Morgenstein. “We continue to increase the depth and breadth of our solutions, and serve as an essential partner in helping clients overcome challenges across their businesses.”

About NFP

NFP is a leading insurance broker and consultant providing specialized property and casualty, corporate benefits, retirement and individual solutions through its licensed subsidiaries and affiliates. NFP enables client success through the expertise of over 5,600 global employees, investments in innovative technologies, and enduring relationships with highly rated insurers, vendors, and financial institutions. NFP is the 5th largest benefits broker by global revenue, 6th largest US-based privately owned broker, and 8th best place to work in insurance (Business Insurance); 10th largest property and casualty agency (Insurance Journal); and 13th largest global insurance broker (Best’s Review).

Visit NFP.com to discover how NFP empowers clients to meet their goals.

Share article on social media or email:

Middle-Mile Logistics Play Evolving Role in U.S. Consumer Supply Chain


“Middle-mile trucking, however, is emerging as perhaps the primary area of competition—and growth—in the U.S. consumer goods supply chain.”

Following a successful pilot trial period in five Northeastern states, Amazon has rolled out its new freight brokerage operation to all 48 contiguous states—a move that will enable the ecommerce giant both to compete with other large digital brokerages and enhance its edge as a retailer during peak shipping season.(1) “In recent years, industry attention on ecommerce logistics has largely focused on last-mile delivery,” says John Kearney, CEO of Advanced Training Systems. “Middle-mile trucking, however, is emerging as perhaps the primary area of competition—and growth—in the U.S. consumer goods supply chain.”

Kearney, whose company is a leading designer and manufacturer of virtual simulators for driver training, among other applications, notes that where last-mile transport refers to the delivery of goods from a fulfillment center to a customer or a retail store, middle-mile shipping is delivery from a point of origin—a factory, for example, or an airport or seaport—to a fulfillment center. Middle-mile transport is customarily provided by digital freight brokers, who connect shippers (individual companies or shipping carriers) with truck drivers—typically using programmed algorithms to match a given delivery with the location, schedule, and capabilities of a given trucker.(2)

While Amazon owns or leases thousands of truck trailers, it has traditionally relied on contractors or brokers to provide the tractors, the power units that house the driver and pull the load. In October of 2019, however, the company announced that it was purchasing heavy-duty tractors from Volvo (as well as possible other suppliers). Amazon’s long-term objective is said to be to gain more control over its supply chain, in which it is working aggressively not only on freight brokerage, but on airfreight service and last-mile parcel deliveries. (3)

Meanwhile, Amazon’s core business, retail ecommerce, has seen explosive growth—driven in part by the COVID-19 pandemic—as U.S. daily ecommerce sales grew 49% in early April over the level of a month earlier.(4) To keep up with demand during the novel coronavirus outbreak and beyond, Amazon has announced plans to hire 100,000 new employees, including drivers, for its warehouse and delivery operations in the U.S.(5)

“And it’s not just Amazon,” Kearney says. “The combination of COVID-19 and an already existing trend toward ecommerce is creating an urgent—and ongoing—need for capable new workers. As leading providers of a technology that has demonstrated, repeatedly, the ability to produce better, safer drivers, we look forward to our continued collaboration with trucking companies, driving schools, shippers, and other players in this essential, thriving, and rapidly changing industry.”

About Advanced Training Systems LLC:

Advanced Training Systems (ATS) is a technology and engineering firm that has revolutionized the design and manufacture of high-tech simulator systems to improve training for operators of all types of motor-powered vehicles. ATS, the holder of multiple patents in its field, is dedicated to providing cutting-edge adaptive training at an affordable cost to all involved in the transportation industry, resulting in more qualified drivers/operators and safer streets. For more information, visit http://www.atstrainingsystems.com.

1. “Aiming to Lock down Truckload Capacity, Amazon Goes Nationwide with Its Freight Brokerage.” Commercial Carrier Journal, 21 May 2020, ccjdigital.com/amazon-freight-brokerage-goes-nationwide/.

2. “What Does A Digital Freight Broker Do?” Redwood Logistics, 17 Feb. 2020, redwoodlogistics.com/what-does-a-digital-freight-broker-do/

3. Solomon, Mark. “Amazon Poised to ‘Double down’ on in-House Truckload Program by Rolling into Power Unit Purchases.” FreightWaves, 13 Oct. 2019, freightwaves.com/news/amazon-poised-to-double-down-on-in-house-truckload-program-by-rolling-into-power-unit-purchases.

4. Ali, Fareeha, et al. “Ecommerce Trends amid Coronavirus Pandemic in Charts.” Digital Commerce 360, 20 May 2020, digitalcommerce360.com/2020/05/20/ecommerce-during-coronavirus-pandemic-in-charts.

5. Lardinois, Frederic. “Amazon Is Looking to Hire 100,000 Employees to Keep up with Demand.” TechCrunch, TechCrunch, 16 Mar. 2020, techcrunch.com/2020/03/16/amazon-is-looking-to-hire-100000-employees-to-keep-up-with-demand.

# # #

Share article on social media or email:

Gene Therapy Company Head Peter Tombros Joins Childhood Cancer Foundation Board of Directors


Peter Tombros

Peter’s extensive experience addressing the unique challenges of biotech research will provide valuable insight to the Foundation’s mission to overcome the barriers that have limited progress in childhood cancer research.

Bridge To A Cure Foundation announced Peter Tombros, Executive Board Chair and Acting CEO of NeuExcell Therapeutics, as the newest member of its Board of Directors.

President and Board of Directors Chairman of Bridge To A Cure Foundation, Robert Martin, welcomed Tombros to the organization. “Peter’s extensive experience addressing the unique challenges of biotech research will provide valuable insight to the Foundation’s mission to overcome the barriers that have limited progress in childhood cancer research,” he explained. “His willingness to join us is testament of the unique approach Bridge To A Cure Foundation is taking to transform childhood cancer research.”

Tombros brings to Bridge To A Cure Foundation leadership in the pharmaceutical industry. His experience includes eight years as President and CEO of Enzon Pharma, where he grew the company into one of the top 20 biotech firms in the United States. Prior to that, Tombros spent over 25 years with Pfizer Inc. in a variety of senior executive positions. He currently serves an emeritus role as Professor and Distinguished Executive in Residence in the Eberly College of Sciences BS/MBA Program at the Pennsylvania State University. In 2015, he was selected “Financial Times 2015 Director of the Year.”

Prior to joining the Board of Directors at Bridge To A Cure Foundation, Tombros served on eight different publicly traded pharmaceutical company boards, and has been involved in a wide variety of board matters including CEO succession, corporate restructuring, financing, regulatory (FDA, SEC) dealings, and corporate governance issues.

About Bridge To A Cure Foundation

Bridge To A Cure Foundation, a 501(c)(3) charitable organization, raises funds to modernize childhood cancer research. Dedicated to healthier, happier kids, the organization’s action plan to accelerate the pace and success of childhood cancer research connects the people, information, and resources needed to propel life-saving cures. For more information, visit BridgeToACure.org.

Share article on social media or email:

The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Clearly, the world ‘post-COVID-19’ will be different from the world where we came from, but what impact can we expect, and what changes may last?

With the emergence of SARS-CoV-2, we all have ‘lost our innocence’ by learning that an unexpected, novel infectious agent has a dramatic and, for today’s generations, unprecedented impact on lives, society, economy and as a consequence, on the domain of clinical drug development. Clearly, the world ‘post-COVID-19’ will be different from the world where we came from, but what impact can we expect, and what changes may last?

This webinar will start exploring clinical drug development in the setting of SARS-CoV-2 being a new entity to deal with, by addressing the questions:


  • What is known about SARS-CoV-2, its epidemiology and how it compares to earlier coronaviruses? What is known about COVID-19, the unexpected variation in its clinical presentation, in adults and in children, and the short- and long-term effects?
  • How can active infection with SARS-CoV-2 be reliably measured and how can previous infection be proved by measuring immune response? How can we find our way in a myriad of tests that are becoming available in a rapid response setting, with limited, if any, regulatory oversight?
  • Now that SARS-CoV-2 is amongst us, how should groups proceed with early clinical development programs, including first-in-human studies, whilst minimizing risk to study participants, maximizing informative value of the study and in compliance with all rules and regulations?
  • COVID-19 has pressure tested clinical drug developers and regulators, and has brought about ad-hoc changes in regulatory approaches. What COVID-19 imposed regulatory changes can be expected to be long-lasting and here to stay?

Join Radboud van Trigt, PhD, Director of Bioanalytical Science – Biomarkers, PRA Health Sciences, Gregory P. Licholai, MD, MBA, Yale School of Management, Chief Medical Officer, PRA Health Sciences and Arwa Shurrab, Senior Director, Regulatory Strategy, PRA Health Sciences in a live webinar on Monday, July 13, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit The Impact of COVID-19 on Early Clinical Development – What the New Landscape Will Look Like.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email: